International pharmaceutical corporation Pfizer opted for Schreiner MediPharm’s Needle-Trap needle protection label to equip the syringes for its epoetin biosimilar. This makes it the first medication for the treatment of anemia to be launched on the market with Needle-Trap–initially in Germany and Austria, to be followed by a successive rollout on the European market.
Pfizer, one of the world's largest pharmaceutical companies, develops innovative medicines and vaccines as well as some of the most popular over-the-counter products. For an epoetin product for the treatment of anemia, the company was looking for a reliable solution to protect healthcare personnel from needlestick injuries when injecting the drug – and decided for Schreiner MediPharm's Needle-Trap once again. Pfizer has already been successfully using this innovative label-based needle protection system on millions of syringes for a heparin drug since 2009.
Needle-Trap features a unique design: The plastic needle trap is an integral component of the label for prefilled syringes and serves to secure the needle after the injection has been performed. Due to its special design, it can be easily integrated into existing pharmaceutical manufacturing processes. Only minor modifications of the finishing and application equipment, no adaptation of secondary packaging and minimal space during shipping, storage and disposal are required.
Needle-Trap meets the requirements of EU Directive 2010/32/EU, U.S. NIOSH for safe instruments and DIN EN ISO 23908 for sharps injury protection. In addition, it has been cleared by an FDA 510(k) Premarket Notification in the United States. Healthcare personnel benefit from reliable protection against needlestick injuries that enables simple and irreversible activation. Use is intuitive and requires no changes to the user’s injection technique as the needle protection is integrated into the syringe label.